TheaimofthisstudywastoexaminetheexpressionofTGF-b1andTGF-breceptortypeII(RII)andtheimpactofthe-509C>Tsinglenucleotidepolymorphism (SNP)inthegeneinrelationtoclinicopathologicalfactorsingastriccancer(GC). Usingimmunohistochemistryweinvestigated43patientswithGCforexpression of TGF-b1 and TGF-b-RII. Consequently, RFLP-PCR was performed to analyze thepresenceof-509C>TpolymorphismintheTGF-b1gene. Wefoundthat72.1%ofGCshadcytoplasmicTGF-b1expressionand27.9%were negative.TheTGF-b1receptortypeIIwasexpressedontumorcellmembranesin 58.1%.TGF-b1positivityintumorcytoplasmcorrelatedpositivelywithTGF-b1-RIIexpressionintumorcytoplasmin67.4%ofcases(χ 2 =8.02;p=0.005).Also, theresultsshowedthatpatientswithlowandmoderatetumordifferentiationhad TGF-b1-RII positivity in 53.3% and 81.8% resp. (χ 2 = 6.58; p = 0,037). The analysisofgenotypedistributionofthe-509C>TSNPinthepromoterregionof TGF-b1geneandclinicalstagedistributionrevealedthatamongthe32patients inIII-IVclinicalstage53.1%wereheterozygous(TC),34.4%werehomozygous fortheC-alleleand12.5%werehomozygousforthevariantT-allele(χ 2 =3.31; p=0.069).
InconclusiontheexpressionofTGF-b1wasrelatedtoshortersurvivaltimeand

Introduction
Gastric cancer (GC) is one of the most common malignanttumorsworldwideandthethirdcauseof neoplasmrelateddeath [1] .Aboutonemillionnew casesofGCwereestimatedtohaveoccurredin2012 (952,000cases,6.8%ofthetotal)makingitthefifth mostcommonmalignancyaftercancersofthelung, breast,colon/rectumandprostate [2] .Differentfactors such as obesity, gastroesophageal reflux disease and chronic gastritis are thought to contribute to its deadliness, and unfortunately between 23% and 34% of the patients were diagnosed in advanced stages [3, 4] .
As the survival rate of patients with GC is rather low, even in the developed countries, apart from thevarietyofprognosticmarkers,newindependent parametersarebeinginvestigated.Todatemanytumor-associatedantigenseitherintracellularoronthe cellsurfacehavebeenidentified.
Transforminggrowthfactorb1(TGF-b1)isamultifunctionalcytokinethatcaninducegrowthinhibi-tion,apoptosis,anddifferentiationofgastrointestinal epithelial cells [4] . TGF-b1 is encoded on chromosome 19q13.1 and it is a 44.3kDa protein that is usuallysecretedasaninactivecompoundconsisting of a homodimer non-covalently linked to a latency-associatedpeptidehomodimer.Theactiveprotein bindstotypeIITGF-b1receptorswhichformhet-erodimerswithTGF-b1typeIreceptors.Thisresults inreceptor-mediatedserine-threoninekinaseactivity involvingphosphorylationofmembersoftheSMAD familyoftranscriptionfactorsandactivation/inhibitionofvariousgenes,dependingonthestateofcell transformation,includinginGC [5, 6, 7, 8] .
Inaddition,thereisnosignificantdatainpublic sources about the role of the -509C>T single nucleotide polymorphism, protein expression and correlations with clinical parameters and progression of GC patients. One previous publication has described a case-control study investigating whether theTGF-b1 -509C>TSNPcanmodifytheriskof gastriccancer [9] .
The aim of the present study was to investigate agroupof43patientswithGCimmunohistochem-ically for TGF-b1 and TGF-b1-RII expression and to analyze the genotype distribution regarding the -509C>TTGF-b1SNPusingRFLP-PCRtechnique. Wealsoevaluatedtherelationbetweenthecollected dataandsomeclinicalandpathologicalparametersof theinvestigatedgroupofpatients. 
Material and methods
Patients and samples
DNA extraction
Genomic DNA was extracted from fresh tumor biopsytissuesusingagenomicDNApurificationkit (NucleoSpin Tissue, Macherey-Nagel, Duren, Germany)andDNAfromthecontrolswasisolatedfrom blood samples (NucleoSpin Blood L, Macherey-Nagel, Duren, Germany) according to manifacturer's protocol. After that extracted DNA was stored at -80°C until further use. The concentration of resulting DNA was measured spectrophotometrically at 260 nm by NanoVue TM Spectrophotometer (Healthcare, Buckinghamshire, UK). The ratio of absorptionsat260vs.280nmwasusedtoassessthe purityoftheDNAsamples.
Genotyping of TGFb1 -509 C>T polymorphism (rs1800469)
Genotyping was performed by PCR restriction lengthpolymorphism(RFLP)assay.ThePCRprimers for amplification of the studied polymorphism were as follows: 5'-CAGTAATGTATGGGGTCG-CAG-3' (forward) and 5'-GGTGTCAGTGGGAG-GAGGG-3'(reverse).SampleDNAwasamplifiedin 20mlofareactionmixture,containing1×PCRbuf-fer, 0.4 mmol/l of each primer, 0.2 mmol/l dNTPs, 1.5mmol/lMgCl 2 ,and1UofTaqpolymerase(FermentasLtd).ThePCRprofileincludedinitialdenaturationat94°Cfor3minutes,followedby35cycles of denaturation at 94°C for 1 minute, annealing at 63°Cfor1minute,andextensionat72°Cfor1min-ute.Finalelongationwasperformedfor7minutesat 72°C.PCRamplificationwasperformedonQCycler (QuantaBiotechLtd,UK). Amplification was checked electroforetically on a 2% agarose gel. The PCR product was digested with 10U Eco81I in a total volume of 20 ml of 1xTango buffer (Fermentas Ltd) at 37°C overnight. Therestrictionyieldstwofragmentsof117bpand 36bpinthepresenceoftheancestralC-allele.The fragments were separated on a 3% agarose gel and stainedwithethidiumbromide(0.5mg/ml).Forall genotype analysis laboratory personal were blinded tosubjects'status;agaroserestrictionfragmentgels wereinterpretedbyatleasttwoindependentreaders.
In each PCR run, heterozygous control template andnegativetemplatecontrolswereusedtoensure accuracy.
Immunohistochemistry
Gastric cancer tissues from all 43 patients were analyzed immunohistochemically. Specimens were fixedin10%bufferedformalin,embeddedinparaffinandthencutto4µmthickness.Nextstepwere dewaxed and endogenous peroxidase was blocked for 5 minutes with blocking reagent according to the protocol. Then the slides were washed 3 times with PBS and incubated with primary antibody for 1 hour. Reactions were carried out with rabbit anti-human TGF-b1 antibody (sc-146, Santa Cruz Biotechnology,USA)inadilution1:50andrabbit anti-humanTGFbRIIantibody(sc-400,SantaCruz Biotechnology,USA)inadilution1:50.Afterthat slideswashing3timestheslideswereincubatedwith detectionsystemEnVision™FLEX+,Mouse,High pH,(Link)(K8002,DAKO)andthenwashedagain. In the last step probes were incubated with DAB substrate-chromogen and contra stained with Mayer'shematoxylin.
Theanalysiswasperformedaccordingtothemanufacturer'sprotocolsandfinalscoreforTGF-b1and TGFbRIIexpressionwereobtainedaccordingtoimmunostainingintensityintumorepithelialcellsand weredesignatedasnegative-score0,orpositive1+.
Statistical analysis
TheSPSS19.0softwareforWindowswasusedfor statistical analysis. The descriptive statistical tests, includingthemean,standarddeviation,andmedian, were calculated according to the standard methods andprogramprotocol.Thefrequencyofdistribution of immunohistochemical staining and the clinicopathological parameters in 2×2 contingency tables wasanalyzedbyχ 2 -test.Survivalwascalculatedfrom thedateofoperationtothedateofdeathorofthelast follow-up.Cumulativesurvivalcurvesweredrawnby theKaplan-Meiermethodantthedifferencebetween curveswasanalyzedbythelog-ranktest.Forallstatisticalanalysis,p<0.05wasconsideredtobestatis-ticallysignificant.
Results
Expression of TGF-b1 and TGF-b1-RII in tumor tissue and corellations with clinical and pathological factors
After immunohistochemical examination we found that 31 cases (72.1%) of GCs had cytoplasmicTGF-b1 expressionand12(27.9%)werenegative (Fig.1A) .SomeofthenormalepithelialandinflammatorycellsalsoweremarkedbyTGF-b1.The TGF-b1receptortypeIIwasexpressedontumorcell membranesin25(58.1%)ofthecancers (Fig.1B) NocorrelationwasobservedbetweenTGF-b1and TGF-b1-RIIexpressionandotherclinicopathological factors(TableIII).
-509C>T TGF-b1 polymorphism correlations
After RFLP-PCR analysis of 43 cases of GCs, 24(55.8%)ofthecaseshadgenotypeTC,15(34.9%) -CC,andtherest4cases(9.3%)hadTTgenotype (Fig.2) . The analysis of genotype distribution of the -509C>T SNP in the promoter region of TGFb1-gene and clinical stage distribution revealed that amongthe32patientsinIII-IVclinicalstage53.1% were heterozygous (TC), 34.4% were homozygous fortheC-alleleand12.5%werehomozygousforthe variant T-allele (χ 2 = 3.31; p = 0.069) (Table III) . Nostatisticallysignificantcorrelationbetweengenotypedistributionandotherparametrswasfound. 
Survivaldatawereavailablefor29patients.
For analyzing the impact of TGF-b1, TGF-b1 receptor type II expression and -509C>T TGF-b1 SNPonthesurvivalaftersurgery,thepatientgroup wasdichotomizedaccordingtoexpressioninGCstissues and polymorphism genotyping. At the end of the follow-up, 10 (34.5%) of the patients survived, withmediansurvivalperiodof25.05months(range from0.3to60.1months).
WithrespecttothestudiedpolymorphismitappearedthatthecarriersofTT-genotypehadtheshortest median survival compared to the carriers of the heterozygote genotype (CT) and the CC-genotype (p=0.024,Log-ranktest; Fig.3A) .Afteranalysisof proteinsexpressionwefoundthatthesurvivaltime wasshorterfortheTGF-b1andTGF-b-RIIpositive cases,comparedwiththesurvivaltimefornegative GCs,althoughthedifferencesdidnotreachstatisticalsignificance(p=0.076andp=0.407Log-rank test; Fig.3B,C) .
Discussion
Asasociallysignificantdiseaseaffectingasmuch as700000peopleworldwideeveryyear [10] ,gastric cancer remains a huge challenge to researchers and intense efforts are put in identifying potential biomarkersfordetectionandearlydiagnosisinorderto beprolongedpatients'survivalandchancesforcure as prognosis is inversely related to the stage of the disease.
According to our obtained data a significant associationbetweenthe-509C>TSNPandthestage of the disease and survival in the patients' group was observed, as well as between the expression of TGF-b1-RII and the differentiation stage of tumor. TherewasnosignificantassociationbetweentheexpressionofTGF-b1andotherfactors. Also, our results indicate the involvement of TGF-b1andotherproteinsoftheTGF-bpathwayat different gastric pathology. In metaplastic and dysplasticlesionsthereactivitytoTGF-b1wasmorein-tensethaninnormalmucosa,andalsotherewasarelation to the histological subtype of GC -a strong reactivity both as intensity and number of positive cells,especiallyinthediffusevariantofthistypeof neoplasms [11] .
In our previous work we have reported that the positiverateofTGF-b1inintestinaltypegastriccan-cers were significantly higher than those in diffuse typegastriccancersanditwaslowerinmoderateand highdifferentiatedtumors.Also,weconcludedthat the TGF-b1 positive patients had a shorter median survivalcomparedtoTGF-b1-negativepatientswho underwentgastrectomryorcurativeresection.Thisis in agreement with our statement that upregulation ofTGF-b1iscommoninvarioustypesofcancer;it isnotcommonlyregardedasaprognosticfactorfor survival [12] .
TGF-b1 is a strong immunosuppressive cytokineproducedbyimmuneandnon-immunecells, including tumor cells. Inhibition of TGF-b1 signalingpathwayhasbeenreportedtopreventprogressionandmetastasisofcertainadvancedtumors [13, 14] . Together with its receptor TGF-b1 receptortypeII,theyhaveapivotalroleintheprogressionandsurvivalofGC.Also,wefoundpublisheddatathatsometumorsarerefractorytothe suppressiveeffectofTGF-b1withthesecretionof TGF-b1 [15] .OurresultsindicateatendencybetweentheexpressionofTGF-b1,TGF-b1-RIIand a shorter post-operative survival in gastric cancer patientswhichseemsinaccordancewiththeaforementionedstudy.
In addition, a functional single nucleotide variationinposition509thofthepromoterregionofthe TGF-b1genehasbeenintensivelystudiedinGCpa-tients.ThisSNPhasbeenreportedtoaffectTGF-b1 expressionandconsequentlyaffectplasmaconcentrationsofcirculatingTGF-b1 [16] andhasbeenrelated to clinicoptahological characteristics of GC patients inseveralstudies [4, 17] .Themolecularmechanism underlyingthedifferentialexpressionofTGF-bdue to the -509C>T SNP has been elucidated in the studyofShahet al. [18] .Theauthorshavedemonstratedthattheactivatorprotein1(AP-1)downregulatesthetranscriptionalactivityofthegenebinding totheancestralC-alleleinthepromoterofTGF-b1. Thus, the presence of the variant T-allele at 509th positionhasbeenassociatedwithhigherplasmaconcentrationsoftheTGF-b1protein,especiallyamong individualshomozygousfortheT-allelethaninheterozygotes.
Although the studies on the association between theTGF-b1-509C>TSNPandGCriskarebecom-ingmoreprevalent,theresultsareconflictingandinconclusive.Inameta-analysisconductedbyLiet al. theauthorsconcludedthatTGF-b1T-alleleisasusceptibility genetic factor for gastric cancer [3, 19] . Furthermore,thestudyhavedemonstratedthatthe TT-genotype was associated with increased GC risk in stages III and IV. In accordance with these data ourresultsindicatethatthecarriersoftheTT-genotypehadshortermediansurvivalthenpatientswith TC-andCC-genotype.Additionally,wehavefound that patients in the III-IV stage of the disease are prevalently homozygous for the T-allele, than patientsinstageI-II.Ourresultsthereforesupportthe thesisreportedbyseveralauthorsthatonceatumor hasdeveloped,TGF-b1promotestumorgrowth,invasionandmetastasis,aswellasinhibitingimmune surveillance.
Conclusively,ourpreliminaryresultsindicatethat theexpressionofTGF-b1,TGF-b1-RIIandtheTTgenotypeof-509C>TpolymorphismofTGF-b1are relatedtoshortersurvivaltimeandrapidprogression fortheGCpatientssuggestingaworseprognosisfor thosepatients.
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